中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 35 Issue 7
Jul.  2019
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(7): 1509-1513

Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.07.018

  • Department of Interventional Radiology, The First Affiliated Hospital of Soochow University

Research funding:

 

  • Received Date: 2019-02-01
  • Published Date: 2019-07-20
    Abstract
  • Objective To investigate the clinical effect and safety of transarterial chemoembolization ( TACE) with ultra-liquid iodized oil combined with drug-eluting beads in the treatment of Barcelona Clinic Liver Cancer ( BCLC) stage B/C hepatocellular carcinoma ( HCC) .Methods A retrospective analysis was performed for the clinical data of 51 patients with BCLC stage B/C HCC who underwent TACE with ultra-liquid iodized oil combined with drug-eluting beads in The First Affiliated Hospital of Soochow University from May 2016 to September 2018. Liver function was observed before treatment and at 3 days, 7 days, and 1 month after treatment, and adverse events and complications were recorded in detail. Modified Response Evaluation Criteria in Solid Tumors was used to evaluate clinical outcome at 1 and 3 months after surgery. The t-test was used for comparison of continuous data between two groups. Results Superselective TACE procedure was completed in all 51 patients. At 1 month after surgery, the target lesions had a disease remission rate of 70. 6% and a disease control rate of 96. 1%, while at 3 months after surgery, the target lesions had a disease remission rate of 64. 0% and a disease control rate of88. 0%. Of all 51 patients, 5 ( 9. 8%) experienced acute liver injury at 3 days after surgery, and there were significant changes in alanine aminotransferase ( ALT) , aspartate aminotransferase, total bilirubin ( TBil) , and albumin ( Alb) ( t =-5. 454, -3. 997, -5. 346, and7. 212, all P < 0. 001) . There were also significant changes in ALT, TBil, and Alb at 7 days after surgery ( t =-3. 177, -3. 665, and3. 194, all P < 0. 05) . Of all 51 patients, 35 ( 68. 6%) experienced grade 1 or 2 adverse events at 1 month after surgery, and no complications of liver failure, liver abscess, bile tumor, and gastrointestinal bleeding were observed. One patient died of multiple organ failure due to tumor progression on day 61 after surgery. Conclusion TACE with ultra-liquid iodized oil combined with drug-eluting beads is safe and effective in the treatment of BCLC stage B/C HCC, and further studies are needed to observe long-term efficacy and survival benefit.

     

    • FullText(HTML)
    • References(22)
  • [1]KAN Z, MADOFF DC.Liver anatomy:Microcirculation of the liver[J].Semin Intervent Radiol, 2008, 25 (2) :77-85.
    [2]LEWIS AL, GONZALEZ MV, LEPPARD SW, et al.Doxorubicin eluting beads-1:Effects of drug loading on bead characteristics and drug distribution[J].J Mater Sci Mater Med, 2007, 18 (9) :1691-1699.
    [3]LEWIS AL, GONZALEZ MV, LLOYD AW, et al.DC bead:In vitro characterization of a drug-delivery device for transarterial chemoembolization[J].J Vase Interv Radiol, 2006, 17 (2 Pt1) :335-342.
    [4]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, andtreatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
    [5] DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury, I.Performance characteristics of laboratory tests[J].Clin Chem, 2000, 46 (12) :2027-2049.
    [6]LAMMER J, MALAGARI K, VOGL T, et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:Results of the PRE-CISION V study[J].Cardiovasc Intervent Radiol, 2010, 33 (1) :41-52.
    [7] RISSE JH, MENZEL C, GRYNWALD F, et al.Therapy of hepatocellular cancer with iodine-131-Lipiodol[J].Rom J Gastroenterol, 2004, 13 (2) :119-124.
    [8]LI SY, WU S, CHEN TS, et al.Effect of portal venous perfusion cinobufacini injection combined with TACE in patients with intermediate hepatocellular carcinoma[J].Clin J Med Offic, 2017, 45 (9) :884-886. (in Chinese) 李淑英, 吴申, 陈挺松, 等.经导管肝动脉栓塞化疗联合华蟾素门静脉灌注治疗中期原发性肝癌疗效研究[J].临床军医杂志, 2017, 45 (9) :884-846.
    [9] HIGASHIHARA H.Transcatheter arterial chemoembolization of hepatocellular carcinoma:A Japanese experience[J].Hepatogastroenterology, 2002, 49 (43) :72-78.
    [10] de BAERE T, DUFAUX J, ROCHE A, et al.Circulatory alterations inducedby intra-arterial injection of iodized oil and emulsions of iodized oiland doxorubicin:experimental study[J].Radiology, 1995, 194 (1) :165-70.
    [11]KAN Z, IVANCEV K, HAGERSTRAND I, et al.In vivo microscopy of the liverafter injection of Lipiodol into the hepatic artery and portal vein inthe rat[J].Acta Radiologica, 1989, 30 (4) :419-425.
    [12]ZHAO BL, CUI XJ, XING H, et al.Clinical effect of transcatheter arterial chemoembolization with iodinated oil combined with microspheres in treatment of large hepatocellular carcinoma[J].Shandong Med J, 2018, 58 (22) :87-89. (in Chinese) 赵邦利, 崔新江, 邢辉, 等.碘化油联合微球经导管肝动脉化疗栓塞治疗大肝癌效果观察[J].山东医药, 2018, 58 (22) :87-89.
    [13]LUO JJ, YAN ZP, WANG JH, et al.HCC embolized by microspheres and iodized oil compared with by iodized oil alone[J].Chin Comput Med Imag, 2008, 14 (2) :154-159. (in Chinese) 罗剑钧, 颜志平, 王建华, 等.微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究[J].中国医学计算机成像杂志, 2008, 14 (2) :154-159.
    [14]ZHANG JX, LI FZ, CHAI J, et al.Clinical and controlled trial of transcatheter arterial chemoembolization with polyvinyl alcohol particle in patients with advanced hepatocellular carcinoma[J].J Hepatopancreatobiliary Surg, 2014, 26 (3) :195-197, 203. (in Chinese) 张军喜, 李发中, 柴健, 等.微球加碘化油栓塞治疗肝癌疗效的临床对照研究[J].肝胆胰外科杂志, 2014, 26 (3) :195-197, 203.
    [15]YOU JX, WANG JB, AI ST, et al.TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma:Analysis of short-term efficacy[J].J Intervent Radiol, 2017, 26 (6) :531-534. (in Chinese) 游建雄, 王精兵, 艾松涛, 等.微球联合碘油栓塞治疗肝癌的近期疗效分析[J].介入放射学杂志, 2017, 26 (6) :531-534.
    [16]NAKAO N, UCHIDA H, KAMINO K, et al.Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis[J].Cardiovasc Intervent Radiol, 1994, 17 (2) :76-80.
    [17]XIAO CJ, ZHENG LY.Clinical effect of transarterial chemoembolization in treatment of liver injury:An analysis of 100 cases[J].Chin J Radiol, 1997, 31 (11) :777-779. (in Chinese) 肖承江, 郑丽吟.肝动脉栓塞化疗对肝损害的观察 (附100例分析) [J].中华放射学杂志, 1997, 31 (11) :777-779.
    [18] DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury.I.Performance characteristics of laboratory tests[J].Clin Chem, 2000, 46 (12) :2027-2049.
    [19]KAN XF, ZHENG CS, XIONG B, et al.Simple conventional hepatic artery chemoembolization for the treatment of Barcelona stage C liver cancer:A clinic analysis[J].J Intervent Radiol, 2018, 27 (12) :1182-1185. (in Chinese) 阚雪锋, 郑传胜, 熊斌, 等.单纯经典肝动脉化疗栓塞术治疗巴塞罗那C期肝癌的临床分析[J].介入放射学杂志, 2018, 27 (12) :1182-1185.
    [20]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:The major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.
    [21]ZHANG MY, NIU JQ.Prevalence of primary liver cancer in Eastern countries and related influencing factors[J].J Clin Hepatol, 2018, 34 (7) :1399-1402. (in Chinese) 张明媛, 牛俊奇.东方国家原发性肝癌发病趋势及影响因素[J].临床肝胆病杂志, 2018, 34 (7) :1399-1402.
    [22]CAO K, BAO ZM, ZHOU XY, et al.Effects and mechanisms of hepatitis B virus X protein on invasion and migration of hepatocellular carcinoma cells[J].Chin J Dig Surg, 2017, 16 (2) :177-182. (in Chinese) 曹宽, 鲍仲明, 周新宇, 等.乙型肝炎病毒X蛋白对肝癌细胞侵袭与迁移能力的作用及机制[J].中华消化外科杂志, 2017, 16 (2) :177-182.
    • Relative Articles

  • Relative Articles

    [1]Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN. Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1886-1890. doi: 10.12449/JCH240926
    [2]Jianan ZHAO, Jinghua PENG, Ping LIU, Yiyang HU. Effect of Cordyceps polysaccharides on hepatocyte apoptosis induced by tumor necrosis factor-α[J]. Journal of Clinical Hepatology, 2021, 37(6): 1368-1372. doi: 10.3969/j.issn.1001-5256.2021.06.029
    [3]Zhen TIAN, Lisha WANG, Naijuan YAO, Yingren ZHAO, Litao RUAN. Role and mechanism of hepatic stellate cells in the pathogenesis of mice with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(3): 642-647. doi: 10.3969/j.issn.1001-5256.2021.03.027
    [4]Lihui ZHANG, Minghao LIU, Wenxia ZHAO. Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 463-466. doi: 10.3969/j.issn.1001-5256.2021.02.045
    [5]Qu Yao, Zhang Wei. Role of cell apoptosis in the pathogenesis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1397-1400. doi: 10.3969/j.issn.1001-5256.2019.06.049
    [6]Gong Jing, Jie XinKe. Effect of endoplasmic reticulum stress and autophagy on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2019, 35(12): 2828-2832. doi: 10.3969/j.issn.1001-5256.2019.12.041
    [7]Gao Si, Zhao XiangXuan, Lu ZaiMing. Role of cell apoptosis regulated by P53 in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1373-1376. doi: 10.3969/j.issn.1001-5256.2017.07.038
    [8]Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
    [9]Pan LiuLan, Jia ShengNan, Ma JingTing, Tai JingHua, Jin ZhenJing. Effect of decoy receptor 3 gene on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1330-1333. doi: 10.3969/j.issn.1001-5256.2016.07.023
    [10]Wang YingChun, Kong WeiZong, Jin QingMei, Chen Juan. Effect of salvianolic acid B on hepatocyte apoptosis in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1325-1329. doi: 10.3969/j.issn.1001-5256.2014.12.022
    [11]Pan YuanWei, Ping Jian, Xu LieMing. Research advances in main signaling pathways for inducing apoptosis of activated hepatic stellate cells[J]. Journal of Clinical Hepatology, 2014, 30(2): 182-185. doi: 10.3969/j.issn.1001-5256.2014.02.021
    [12]Wang XiXun, Jiang LiXin, Wang JingLin, Liang Jing, Zhai HuiYuan, Xia XianMing. Experimental study on hepatocyte apoptosis induced by acute biliary tract infection[J]. Journal of Clinical Hepatology, 2014, 30(11): 1164-1168. doi: 10.3969/j.issn.1001-5256.2014.11.018
    [13]Weng ShanGeng, Xu ChangGuo, Sun Ying, Shi Zheng, Lin LiJuan. Study on the apoptosis of rat hepatic stellate cells induced by kapamycin[J]. Journal of Clinical Hepatology, 2012, 28(3): 219-222.
    [14]Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.
    [15]Cheng Rui, Cai XinRan, Zhou HaoHui, Han ShengHua, Zhu JinHai, Chen HuiXing, Chen YanLing. Omega-3 polyunsaturated fatty acids inhibit inflammation during the early stage of acute pancreatitis[J]. Journal of Clinical Hepatology, 2012, 28(8): 598-602.
    [16]Zhang LiLi, Guo XiaoHong, Liu LiXin, Zhang QianQian. IGFBPrP1 siRNA induced apoptosis in rat hepatic stellate cells and its mechanism[J]. Journal of Clinical Hepatology, 2011, 27(9): 965-969+979.
    [17]Zhang Biao, Sui Tao, Yu XiuYing, Cao YongXian, Yao Yuan, He Hong. Significance of detecting apoptosis of PBMC and cytokine of supernatant induced by PHA in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2004, 20(3): 138-140.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(2)

    1. 马宏涛，李璐辰，刘汝杰，李润东，王磊. 水飞蓟宾联合阿昔莫司口服治疗非酒精性脂肪性肝炎的疗效及安全性观察. 山东医药. 2024(14): 49-52 .
    2. 肖炜，王欣鑫，张坪，周斌，唐奇志，李世香. 从病因病机共性探讨2型糖尿病、非酒精性脂肪性肝病与高尿酸血症内在联系. 中国中医药图书情报杂志. 2024(06): 13-17 .

    Other cited types(2)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 53.5 %FULLTEXT: 53.5 %META: 40.6 %META: 40.6 %PDF: 5.9 %PDF: 5.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.5 %其他: 8.5 %其他: 1.0 %其他: 1.0 %Kao-sung: 0.2 %Kao-sung: 0.2 %Toyoake: 0.1 %Toyoake: 0.1 %[]: 0.1 %[]: 0.1 %上海: 5.6 %上海: 5.6 %丽水: 0.1 %丽水: 0.1 %佛山: 0.5 %佛山: 0.5 %保定: 0.1 %保定: 0.1 %兰州: 0.2 %兰州: 0.2 %北京: 4.9 %北京: 4.9 %南京: 0.5 %南京: 0.5 %南充: 0.1 %南充: 0.1 %南宁: 0.3 %南宁: 0.3 %南昌: 0.2 %南昌: 0.2 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %厦门: 0.4 %厦门: 0.4 %台北: 0.1 %台北: 0.1 %台州: 0.9 %台州: 0.9 %吉林: 0.4 %吉林: 0.4 %呼和浩特: 0.1 %呼和浩特: 0.1 %哈尔滨: 0.2 %哈尔滨: 0.2 %嘉兴: 0.2 %嘉兴: 0.2 %天津: 0.2 %天津: 0.2 %太原: 0.5 %太原: 0.5 %威海: 0.1 %威海: 0.1 %孝感: 0.2 %孝感: 0.2 %孟买: 0.2 %孟买: 0.2 %宣城: 0.1 %宣城: 0.1 %常州: 0.2 %常州: 0.2 %常德: 0.1 %常德: 0.1 %广州: 1.5 %广州: 1.5 %弗吉: 0.1 %弗吉: 0.1 %张家口: 2.1 %张家口: 2.1 %徐州: 0.1 %徐州: 0.1 %成都: 0.9 %成都: 0.9 %新德里: 0.1 %新德里: 0.1 %无锡: 0.1 %无锡: 0.1 %昆明: 0.3 %昆明: 0.3 %晋中: 0.1 %晋中: 0.1 %朝阳: 0.1 %朝阳: 0.1 %杭州: 1.4 %杭州: 1.4 %武汉: 1.5 %武汉: 1.5 %水原: 0.1 %水原: 0.1 %沈阳: 0.3 %沈阳: 0.3 %沧州: 0.1 %沧州: 0.1 %法尔肯施泰因: 1.8 %法尔肯施泰因: 1.8 %泰州: 0.3 %泰州: 0.3 %泸州: 0.1 %泸州: 0.1 %洛杉矶: 0.1 %洛杉矶: 0.1 %洛阳: 0.5 %洛阳: 0.5 %济南: 0.2 %济南: 0.2 %济宁: 0.2 %济宁: 0.2 %海口: 0.4 %海口: 0.4 %海得拉巴: 0.4 %海得拉巴: 0.4 %淄博: 0.2 %淄博: 0.2 %深圳: 0.1 %深圳: 0.1 %湖州: 0.4 %湖州: 0.4 %湘潭: 0.1 %湘潭: 0.1 %湛江: 0.1 %湛江: 0.1 %漯河: 0.2 %漯河: 0.2 %牡丹江: 0.2 %牡丹江: 0.2 %石家庄: 0.2 %石家庄: 0.2 %福州: 0.2 %福州: 0.2 %红河: 0.1 %红河: 0.1 %纽约: 0.1 %纽约: 0.1 %罗奥尔凯埃: 0.1 %罗奥尔凯埃: 0.1 %芒廷维尤: 39.1 %芒廷维尤: 39.1 %芝加哥: 0.7 %芝加哥: 0.7 %苏州: 0.3 %苏州: 0.3 %苏拉卡尔塔: 0.2 %苏拉卡尔塔: 0.2 %莫斯科: 0.1 %莫斯科: 0.1 %衡水: 0.2 %衡水: 0.2 %衡阳: 0.1 %衡阳: 0.1 %衢州: 1.0 %衢州: 1.0 %襄阳: 0.1 %襄阳: 0.1 %西宁: 8.2 %西宁: 8.2 %西安: 1.3 %西安: 1.3 %诺沃克: 0.3 %诺沃克: 0.3 %贵阳: 0.3 %贵阳: 0.3 %赣州: 0.3 %赣州: 0.3 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %连云港: 0.1 %连云港: 0.1 %通辽: 0.1 %通辽: 0.1 %邯郸: 0.4 %邯郸: 0.4 %郑州: 0.6 %郑州: 0.6 %重庆: 0.6 %重庆: 0.6 %铜仁: 0.1 %铜仁: 0.1 %锦州: 0.1 %锦州: 0.1 %长春: 1.0 %长春: 1.0 %长沙: 1.4 %长沙: 1.4 %长治: 0.1 %长治: 0.1 %阿什本: 0.8 %阿什本: 0.8 %阿坝: 0.1 %阿坝: 0.1 %青岛: 0.3 %青岛: 0.3 %鞍山: 0.1 %鞍山: 0.1 %鸡西: 0.1 %鸡西: 0.1 %黄石: 0.2 %黄石: 0.2 %其他其他Kao-sungToyoake[]上海丽水佛山保定兰州北京南京南充南宁南昌卡纳塔克厦门台北台州吉林呼和浩特哈尔滨嘉兴天津太原威海孝感孟买宣城常州常德广州弗吉张家口徐州成都新德里无锡昆明晋中朝阳杭州武汉水原沈阳沧州法尔肯施泰因泰州泸州洛杉矶洛阳济南济宁海口海得拉巴淄博深圳湖州湘潭湛江漯河牡丹江石家庄福州红河纽约罗奥尔凯埃芒廷维尤芝加哥苏州苏拉卡尔塔莫斯科衡水衡阳衢州襄阳西宁西安诺沃克贵阳赣州赤峰运城连云港通辽邯郸郑州重庆铜仁锦州长春长沙长治阿什本阿坝青岛鞍山鸡西黄石

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1626) PDF downloads(288) Cited by(4)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2490]YesterdayPV[5108]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return